Allogene Therapeutics (NASDAQ:ALLO) Given Outperform Rating at William Blair

Allogene Therapeutics (NASDAQ:ALLO)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a report released on Thursday,RTT News reports.

ALLO has been the subject of several other research reports. Oppenheimer initiated coverage on Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target for the company. Piper Sandler cut their price target on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Citigroup upped their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Canaccord Genuity Group cut their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Stock Performance

NASDAQ ALLO traded down $0.26 on Thursday, reaching $2.46. The stock had a trading volume of 2,621,827 shares, compared to its average volume of 2,464,115. Allogene Therapeutics has a 12-month low of $2.01 and a 12-month high of $5.78. The business’s 50-day moving average price is $2.75 and its 200 day moving average price is $2.66. The stock has a market cap of $515.79 million, a P/E ratio of -1.58 and a beta of 0.84.

Institutional Trading of Allogene Therapeutics

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in Allogene Therapeutics by 541.5% in the third quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company’s stock valued at $130,000 after purchasing an additional 39,145 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Allogene Therapeutics by 1.2% in the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after purchasing an additional 5,642 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Allogene Therapeutics in the third quarter valued at $116,000. Curi RMB Capital LLC grew its holdings in Allogene Therapeutics by 47.5% in the third quarter. Curi RMB Capital LLC now owns 149,577 shares of the company’s stock valued at $419,000 after purchasing an additional 48,202 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Allogene Therapeutics by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 40,219 shares of the company’s stock valued at $113,000 after purchasing an additional 15,690 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).